Taimei Medical Technologies Secures $80 Million Series E Funding to Accelerate AI-Driven Drug Development Platform
On January 25, VCBeat (WeChat Official Account: vcbeat) exclusively learned that Taimei Medical Technology, a well-known Chinese provider of technical solutions in the life sciences sector, had secured an $80 million Series E financing round. The round was led by Tiger Global Management, with participation from SoftBank China and Kaifeng Venture Capital. VCBeat conducted an exclusive remote interview with Mr. Zhao Lu, CEO of Taimei Medical Technology, immediately after the announcement.
Zhao Lu stated, “Following this round of financing, the company will continue to focus on its core strategies: first, strengthening the development of its integrated pharmaceutical R&D platform, which is the foundation of Taimei Medical Technology; and second, expanding into other areas of demand within the pharmaceutical sector, such as pharmaceutical marketing.”
It is reported that investors in this round are optimistic about the market trends of China’s pharmaceutical industry. Overall, the increasingly standardized national regulations have promoted development in areas such as pharmaceutical R&D, pharmacovigilance, and marketing. Taimei Medical Technology has established competitive advantages within the domestic market, built its own competitive barriers, and gained consistent recognition from customers in brand building.
Amid policy environments such as the “4+7” volume-based procurement, which not only emphasize greater industry standardization but also encourage the development of innovative and originator drugs, technology-driven companies like Taimei Medical Technology have been propelled forward.
From Traditional EDC to AI-Driven EDC
It is reported that Taimei Medical Technology Co., Ltd. is a provider of technology solutions in the life sciences sector. With deep insights into clinical research and pharmacovigilance, the company has independently developed a suite of informatics systems from a professional perspective and with leading technologies. These systems include eCooperate (CTMS), eCollect (EDC), eArchive (eTMF), eBalance (IWRS), eReport (ePRO), eCollege (TMS), MIRS, and the eSafety pharmacovigilance system, covering the entire lifecycle of clinical research.
Building on this foundation, Taimei Medical Technology has innovatively introduced the concept of collaborative clinical research, leveraging technology to create a platform that facilitates collaboration among sponsors, investigators, research institutions, patients, regulatory authorities, and third-party service providers. This platform is implemented through six core solutions: data management, project management, electronic submission, central imaging, pharmacovigilance, and pharmaceutical logistics. By empowering enterprises in the life sciences sector, it enhances R&D efficiency and quality, reduces development costs, and accelerates the market launch of new drugs.
Taimei Medical Technology serves traditional pharmaceutical companies, innovative pharmaceutical enterprises, CROs, and research institutions. To date, the company has entered into strategic agreements and conducted in-depth business collaborations with more than 200 leading pharmaceutical companies and CROs both domestically and internationally. These partners include global pharmaceutical giants such as GlaxoSmithKline and AstraZeneca, as well as top-tier Chinese pharmaceutical companies like Hengrui Medicine and Simcere Pharmaceutical.
Taimei Medical Technology’s products have undergone five major version iterations. The first two generations were in a follow-up phase, appearing somewhat immature compared to internationally renowned products. Starting with the third generation, the company’s products began to exhibit significant differentiation from other similar offerings.
Taking eCollect as an example, the fifth-generation TaiMei eCollect® has begun to establish unique advantages when compared with products from international companies. This edge is primarily driven by the integration of artificial intelligence technology.
Although previous products already possessed some automated logic verification capabilities, many complex checks remained beyond the system’s reach, necessitating data export for manual review and verification. In the latest generation of products, by encapsulating more functions and employing more precise methods for data point acquisition, it is now possible to perform more complex cross-data validations across pages and visits.
Meanwhile, Taimei Medical Technology has implemented AI-assisted decision-making to assess the association between concomitant medications and adverse events, thereby supporting data management, reducing manual verification time for data managers, and improving accuracy.
Furthermore, the latest generation of products incorporates a universal medical terminology dictionary. For standard terms, automatic coding can be achieved by cross-referencing the dictionary and automatically mapping to the main axis chain, thereby improving coding efficiency.
China's First Pharmacovigilance System Integrated with the FDA FAERS
In January 2018, Taimei Medical Technology’s eSafety pharmacovigilance system passed the E2B submission testing for the FDA’s FAERS system and obtained access to the production environment. This means that by using Taimei Medical Technology’s eSafety pharmacovigilance system, post-marketing individual case safety reports can be easily submitted to the FDA in electronic E2B format, thereby meeting FDA regulatory requirements.
In 2015, the FDA issued a Final Rule requiring that post-marketing safety reports be submitted electronically. Among these, submissions using the internationally recognized ICH E2B standard (Individual Case Safety Report transmission standard) became the primary method for submitting individual case safety reports to the FDA. The E2B submission function of Taimei Medical Technology’s eSafety pharmacovigilance system was also developed during this period; however, testing and validation were postponed due to the lack of domestic demand at that time.
In 2017, the internationalization of China’s pharmaceutical affairs accelerated, with a rapid surge in demand for overseas business expansion among Chinese pharmaceutical companies and a growing market need for E2B submissions in China. Taimei Medical Technology intensified its efforts, maintaining close communication with officials responsible for electronic submissions to the FDA FAERS system to seek operational guidance. In coordination with the R&D department’s relentless efforts and technical breakthroughs, the e-Safety pharmacovigilance system successfully passed the FDA FAERS system testing.
Since then, individual case safety reports in the eSafety pharmacovigilance system can be automatically translated and exported into E2B format files that comply with ICH E2B data standards and message specifications, and directly submitted to the FDA FAERS system.
In 2015, Taimei Medical Technology received angel investment from Kaifeng Ventures. In 2016, it secured Series A funding from Matrix Partners China. This was followed by a Series B round led by Northern Light Venture Capital, with participation from Matrix Partners China and Kaifeng Ventures. In 2017, the company completed its Series C financing, led by Yansheng Capital, with follow-on investments from Matrix Partners China, Northern Light Venture Capital, and Kaifeng Ventures. In 2018, Taimei Medical Technology closed a RMB 300 million Series D round, with investors including SAIF Partners, Morningside Venture Capital, Zheshang Venture Capital, SoftBank China, and Ivy Capital.
For a deeper understanding of Taimei Medical Technology, please refer to the following information:
Is the Innovative Drug Market Booming? Has China’s EDC Sector Entered a Phase of Fierce Competition?
Taimei Medical Technology Officially Announces Completion of RMB 100 Million Series C Financing